BOSTON – October 14, 2025 – BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Astria Therapeutics, Inc. (NASDAQ: ATXS) announced a definitive agreement under which BioCryst will acquire Astria in a cash-and-stock transaction. The deal, with an enterprise value of approximately $700 million and an implied per-share value of $13.00, was unanimously approved by both companies’ boards. The acquisition is expected to close in Q1 2026, subject to regulatory approvals and customary closing conditions.
Science Significance
The acquisition significantly enhances BioCryst’s scientific pipeline with Astria’s lead candidate, navenibart (STAR-0215), a long-acting injectable monoclonal antibody inhibitor of plasma kallikrein in clinical development for hereditary angioedema (HAE) prophylaxis. Navenibart offers a highly differentiated dosing schedule of every 3 to 6 months, addressing the unmet needs of HAE patients who require less frequent, pain-free treatment. Early clinical trials of navenibart have demonstrated strong efficacy, favorable safety, and excellent tolerability, supporting its potential to become a best-in-class injectable therapy. BioCryst will also acquire Astria’s early-stage STAR-0310 program, an investigational OX40 antagonist for atopic dermatitis, providing future opportunities for rare disease innovation. This expansion demonstrates a continued commitment to immunologic and allergic disease research.
Regulatory Significance
Navenibart is currently in Phase 3 clinical development, with top-line data from the pivotal ALPHA-ORBIT trial expected in early 2027. BioCryst’s established regulatory expertise in HAE positions the company to effectively navigate FDA and global regulatory pathways, maximizing the potential for timely approvals and broader patient access. The acquisition also maintains strong governance continuity, with Jill C. Milne, Ph.D., CEO of Astria, joining the BioCryst board post-closing. This integration ensures scientific oversight and alignment of clinical strategy, while adhering to regulatory best practices for rare disease biologics.
Business Significance
Advertisement
The acquisition is expected to drive double-digit revenue growth over the next decade. With navenibart complementing Orladeyo® (berotralstat), the first oral HAE therapy, BioCryst now offers both oral and injectable treatment options, giving physicians and patients a more comprehensive, individualized care strategy. Financially, the transaction is anticipated to be non-GAAP profitable and cash-flow positive post-closing, while leveraging operational synergies from BioCryst’s established commercialization infrastructure. Astria shareholders will retain approximately 15% of pro forma equity in the combined company, ensuring alignment of interests and continuity of stakeholder value.
Patients’ Significance
For patients with HAE, navenibart represents a potentially transformative therapy, offering less frequent, pain-free prophylaxis and addressing limitations of existing injectable options. The highly differentiated dosing schedule may improve adherence, quality of life, and attack control. Combined with Orladeyo, BioCryst now provides flexible treatment choices that support individualized disease management, fulfilling a critical gap in rare disease care. Additionally, the acquisition highlights the potential for future innovation in atopic dermatitis via Astria’s STAR-0310 program, expanding patient access to novel immunologic therapies in broader allergic disease areas.
Policy Significance
The transaction aligns with global healthcare policy priorities, including accelerated regulatory pathways for therapies that address unmet medical needs, particularly in rare diseases. By expanding access to navenibart and Orladeyo, the combined company supports patient-centered care and innovation-driven policy objectives. Moreover, the acquisition demonstrates investor confidence in rare disease biopharma, reflecting the strategic importance of portfolio diversification, commercialization expertise, and advanced biologics in public health policy discussions.
Transaction Highlights
Under the terms of the agreement, BioCryst will acquire all outstanding shares of Astria Therapeutics for a combination of $8.55 in cash and 0.59 shares of BioCryst common stock per Astria share, representing an implied per-share value of $13.00. This consideration reflects a premium of approximately 53% over Astria’s closing price on October 13, 2025, and 71% over its 20-day VWAP, resulting in an enterprise value of approximately $700 million and aggregate equity value of roughly $920 million. Astria stockholders are expected to retain around 15% of the pro forma equity in the combined company. The cash portion of the transaction will be funded using BioCryst’s existing cash reserves, supplemented by a strategic $550 million financing facility arranged with funds managed by Blackstone. The deal has received unanimous approval from the Boards of Directors of both companies and is anticipated to close in Q1 2026, pending regulatory approvals, customary closing conditions, and Astria stockholder consent. Key Astria stockholders, including directors, executive officers, and affiliates of Perceptive Advisors, the largest investor, have entered into voting and support agreements in favor of the transaction. Financially, the acquisition is expected to be accretive to BioCryst’s non-GAAP operating profit in the first full year following navenibart’s anticipated launch. By leveraging BioCryst’s established commercialization infrastructure, the transaction is positioned to accelerate navenibart’s market penetration, enhance patient access, and support a long-term double-digit revenue growth trajectory while maintaining positive cash flow and strong near-term financial performance.
Source: Astria Therapeutics, Inc. Press Release
